tiprankstipranks
Trending News
More News >
Sino Biopharmaceutical Ltd (HK:1177)
:1177
Hong Kong Market

Sino Biopharmaceutical (1177) Ratios

Compare
10 Followers

Sino Biopharmaceutical Ratios

HK:1177's free cash flow for Q2 2024 was ¥0.82. For the 2024 fiscal year, HK:1177's free cash flow was decreased by ¥ and operating cash flow was ¥0.22. See a summary of the company’s cash flow.
Ratios
TTM
Dec 23Dec 22Dec 21Dec 20
Liquidity Ratios
Current Ratio
1.05 1.29 1.53 2.08 3.07
Quick Ratio
0.96 1.17 1.41 1.91 2.86
Cash Ratio
0.42 0.43 0.63 0.97 1.31
Solvency Ratio
0.13 0.23 0.68 0.24 0.34
Operating Cash Flow Ratio
0.27 0.31 0.35 0.49 0.66
Short-Term Operating Cash Flow Coverage
0.54 0.64 0.81 3.43 7.99
Net Current Asset Value
¥ -1.63B¥ -185.83M¥ 688.86M¥ -2.00B¥ 6.90B
Leverage Ratios
Debt-to-Assets Ratio
0.20 0.22 0.20 0.30 0.15
Debt-to-Equity Ratio
0.41 0.47 0.40 0.85 0.28
Debt-to-Capital Ratio
0.29 0.32 0.29 0.46 0.22
Long-Term Debt-to-Capital Ratio
0.03 0.12 0.15 0.42 0.20
Financial Leverage Ratio
2.09 2.15 2.00 2.82 1.87
Debt Service Coverage Ratio
0.53 0.58 2.57 3.13 7.22
Interest Coverage Ratio
11.68 15.24 61.11 15.12 25.26
Debt to Market Cap
0.17 0.18 0.14 0.12 0.07
Interest Debt Per Share
0.56 0.77 0.66 0.77 0.47
Net Debt to EBITDA
0.45 0.80 0.13 0.55 -0.27
Profitability Margins
Gross Profit Margin
80.95%79.86%80.15%78.08%79.67%
EBIT Margin
22.54%19.61%70.29%22.57%24.43%
EBITDA Margin
26.64%23.25%73.99%27.67%30.40%
Operating Profit Margin
22.08%23.25%70.21%20.67%23.97%
Pretax Profit Margin
20.65%20.08%69.14%21.20%23.04%
Net Profit Margin
8.90%17.38%54.38%18.36%19.37%
Continuous Operations Profit Margin
17.61%15.70%61.85%18.36%19.76%
Net Income Per EBT
43.10%86.57%78.66%86.59%84.07%
EBT Per EBIT
93.50%86.37%98.47%102.55%96.13%
Return on Assets (ROA)
3.67%7.81%24.13%9.19%8.05%
Return on Equity (ROE)
7.65%16.82%48.23%25.92%15.09%
Return on Capital Employed (ROCE)
14.11%15.24%41.73%13.48%11.58%
Return on Invested Capital (ROIC)
9.45%10.77%32.50%11.18%9.60%
Return on Tangible Assets
3.72%8.05%24.83%9.65%13.24%
Earnings Yield
3.28%6.66%17.50%3.66%3.84%
Efficiency Ratios
Receivables Turnover
5.70 6.20 6.27 8.11 8.94
Payables Turnover
3.74 3.08 2.97 2.66 2.72
Inventory Turnover
2.50 2.49 2.75 2.76 2.97
Fixed Asset Turnover
2.64 3.11 3.15 3.30 3.47
Asset Turnover
0.41 0.45 0.44 0.50 0.42
Working Capital Turnover Ratio
7.50 4.13 2.68 1.65 1.89
Cash Conversion Cycle
112.22 86.92 68.02 40.21 29.67
Days of Sales Outstanding
64.03 58.89 58.23 44.98 40.85
Days of Inventory Outstanding
145.82 146.67 132.64 132.42 122.89
Days of Payables Outstanding
97.63 118.64 122.85 137.19 134.07
Operating Cycle
209.85 205.56 190.87 177.39 163.74
Cash Flow Ratios
Operating Cash Flow Per Share
0.26 0.34 0.29 0.28 0.28
Free Cash Flow Per Share
0.19 0.24 0.19 0.18 0.19
CapEx Per Share
0.07 0.09 0.10 0.10 0.09
Free Cash Flow to Operating Cash Flow
0.72 0.73 0.65 0.65 0.67
Dividend Paid and CapEx Coverage Ratio
2.60 2.11 1.89 1.75 2.09
Capital Expenditure Coverage Ratio
3.56 3.67 2.83 2.86 3.07
Operating Cash Flow Coverage Ratio
0.48 0.45 0.44 0.37 0.62
Operating Cash Flow to Sales Ratio
0.23 0.22 0.20 0.23 0.22
Free Cash Flow Yield
6.14%6.07%4.16%2.92%2.94%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
30.45 15.02 5.71 27.33 26.02
Price-to-Sales (P/S) Ratio
2.71 2.61 3.11 5.02 5.04
Price-to-Book (P/B) Ratio
2.33 2.53 2.76 7.08 3.93
Price-to-Free Cash Flow (P/FCF) Ratio
16.28 16.48 24.04 34.22 34.02
Price-to-Operating Cash Flow Ratio
11.71 11.99 15.55 22.28 22.94
Price-to-Earnings Growth (PEG) Ratio
-0.43 -0.23 0.02 -3.42 -0.53
Price-to-Fair Value
2.33 2.53 2.76 7.08 3.93
Enterprise Value Multiple
10.62 12.03 4.33 18.68 16.31
EV to EBITDA
10.62 12.03 4.33 18.68 16.31
EV to Sales
2.83 2.80 3.20 5.17 4.96
EV to Free Cash Flow
17.00 17.65 24.76 35.26 33.46
EV to Operating Cash Flow
12.22 12.84 16.02 22.95 22.56
Tangible Book Value Per Share
1.59 1.93 1.92 1.07 0.93
Shareholders’ Equity Per Share
1.30 1.60 1.61 0.89 1.65
Tax and Other Ratios
Effective Tax Rate
0.15 0.13 0.11 0.13 0.16
Revenue Per Share
1.12 1.55 1.43 1.26 1.29
Net Income Per Share
0.10 0.27 0.78 0.23 0.25
Tax Burden
0.43 0.87 0.79 0.87 0.84
Interest Burden
0.92 1.02 0.98 0.94 0.94
Research & Development to Revenue
0.17 0.15 0.14 0.11 0.10
SG&A to Revenue
0.07 0.08 0.08 0.11 0.11
Stock-Based Compensation to Revenue
<0.01 <0.01 0.00 0.00 0.00
Income Quality
1.02 1.08 0.29 1.06 0.95
Currency in CNY
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis